S. Opal

发表

Concept of PIRO as a new conceptual framework to understand sepsis

S. Opal, 2005, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

Immunomodulatory therapy for sepsis: an update

Panagiota Anyfanti, P. Anyfanti, S. Opal, 2011, Expert review of anti-infective therapy.

Potential hazards of combination immunotherapy in the treatment of experimental septic shock.

S. Opal, A. Cross, J. Jhung, 1996, The Journal of infectious diseases.

Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.

Jeremy C. Weiss, David T. Huang, Corrine F. Elliott, 2019, JAMA.

Anti-inflammatory cytokines.

S. Opal, V. DePalo, 2000, Chest.

Sepsis and septic shock

R. Hotchkiss, J. Vincent, L. Moldawer, 2016, Nature Reviews Disease Primers.

Notice

Norbert Lameire, John A. Kellum, Steven M. Opal, 2012, Kidney International Supplements.

A common-source outbreak of Staphylococcus epidermidis infections among patients undergoing cardiac surgery.

J. Boyce, A. Medeiros, S. Opal, 1990, The Journal of infectious diseases.

Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance

J. Boyce, A. Medeiros, S. Opal, 1994, Journal of clinical microbiology.

Frequent acquisition of multiple strains of methicillin-resistant Staphylococcus aureus by healthcare workers in an endemic hospital environment.

J. Musser, D. Dickensheets, S. Opal, 1990 .

Spread of methicillin-resistant Staphylococcus aureus in a hospital after exposure to a health care worker with chronic sinusitis.

J. Boyce, A. Medeiros, S. Opal, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The dysfunctional host response to influenza A H7N9: a potential treatment option?

S. Opal, D. Fedson, 2014, Critical Care.

Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia

S. Opal, J. Palardy, N. Parejo, 2003, Critical care medicine.

Endotoxin as a drug target

S. Opal, T. Glück, 2003, Critical care medicine.

Immunocompromised Animals in Sepsis Research

S. Opal, A. Cross, 1998 .

Molecular Targets for Therapy

S. Opal, A. Kalil, 2017 .

The nexus between systemic inflammation and disordered coagulation in sepsis

S. Opal, 2004, Journal of endotoxin research.

Interactions between Coagulation and Inflammation

S. Opal, 2003, Scandinavian journal of infectious diseases.

Plasmid-mediated beta-lactamases

A. Medeiros, S. Opal, K. Mayer, 1988 .

Phylogenetic and functional relationships between coagulation and the innate immune response.

S. Opal, 2000, Critical care medicine.

Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.

S. Opal, J. Vincent, S. Opal, 1999, The Journal of infectious diseases.

Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia

S. Opal, M. Christ-Crain, 2010, Critical care.

Severe Pneumonia Caused by Legionella pneumophila

A. Chahin, S. Opal, 2017, Infectious Disease Clinics of North America.

Antibiotic-Induced D-Lactic Acidosis

S. Opal, S. Opal, B. E. Coronado, 1995, Annals of Internal Medicine.

Relapse of Pneumocystis carinii pneumonia in the upper lobes during aerosol pentamidine prophylaxis.

S. Opal, F. Mccool, R. M. Bradburne, 1989, Thorax.

Sepsis studies need new direction.

T. Calandra, S. Opal, Jonathan Cohen, 2012, The Lancet. Infectious diseases.

Interactions with the compromised host.

S. Opal, A. Cross, 2002 .

Direct sequence detection of structured h5 influenza viral RNA.

Matthew B. Kerby, S. Opal, A. Artenstein, 2008, The Journal of molecular diagnostics : JMD.

Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

S. Opal, A. Cross, A. Artenstein, 2010, Vaccine.

Antibacterial therapy in patients with malignancies

S. Opal, K. Mayer, 2004, Cancer and Metastasis Reviews.

A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.

L. Moldawer, E. Bulger, G. Maislin, 2014, JAMA Surgery.

Antithrombin, heparin, and heparan sulfate

S. Opal, C. Kessler, S. Knaub, 2002, Critical care medicine.

Coagulation abnormalities in critically ill patients

S. Opal, M. Levi, 2006, Critical care.

Infectious Diseases: Third Edition

Jonathan D. Cohen, S. Opal, W. Powderly, 2010 .

Antibiotic-resistant genes in gram-positive bacterial pathogens

S. Opal, 2000 .

Staphylococcal scalded skin syndrome in two immunocompetent adults caused by exfoliatin B-producing Staphylococcus aureus

S. Opal, A. Cross, A. Johnson-Winegar, 1988, Journal of clinical microbiology.

Prevention of opportunistic infections

Jonathan D. Cohen, S. Opal, W. Powderly, 2010 .

Recurrent Burkholderia gladioli Suppurative Lymphadenitis associated with Neutralizing Anti-IL-12p70 Autoantibodies

S. Holland, S. Opal, Lindsey B. Rosen, 2013, Journal of Clinical Immunology.

Pathogenesis, treatment, and prevention of pneumococcal pneumonia

S. Opal, T. Poll, 2009, The Lancet.

Splenectomy and splenic dysfunction

S. Opal, 2010 .

The role of genetics and antibodies in sepsis.

S. Opal, E. Giamarellos‐Bourboulis, 2016, Annals of translational medicine.

Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)

M. Singer, M. Shankar-Hari, J. Vincent, 2018, Intensive Care Medicine.

Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection

S. Opal, H. Palmer, J. Palardy, 2007, Critical care.

The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis

S. Opal, A. Creasey, John E. Palardy, BA, 2001, Critical care medicine.

Middle East respiratory syndrome (MERS)

S. Opal, C. Cunha, 2014, Virulence.

Over-distension of the airways by mechanical ventilation in the elderly: adding insult to injury

S. Opal, A. Pop-Vicas, 2013, Critical Care.

Early In Vitro Transcription Termination in Human H5 Influenza Viral RNA Synthesis

Matthew B. Kerby, S. Opal, A. Artenstein, 2011, Applied biochemistry and biotechnology.

Subtyping Clinical Specimens of Influenza A Virus by Use of a Simple Method To Amplify RNA Targets

S. Opal, A. Artenstein, A. Tripathi, 2013, Journal of Clinical Microbiology.

A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes.

S. Opal, A. Cross, G. Ramachandran, 2013, The Journal of infectious diseases.

Frequent Acquisition of Multiple Strains of Methicillin-Resistant Staphylococcus aureus by Healthcare Workers in an Endemic Hospital Environment

J. Musser, D. Dickensheets, S. Opal, 1990, Infection Control & Hospital Epidemiology.

Coagulation Abnormalities in the Critically Ill

S. Opal, M. Levi, 2010 .

Review Coagulation abnormalities in critically ill patients

S. Opal, M. Levi, 2006 .

Host Microbicidal Actions of the Innate Immune Response

S. Opal, R. L. Yap, 2003 .

Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?

S. Opal, Eirini Christaki, N. Lazaridis, 2012, Current opinion in infectious diseases.

Community acquired pneumonia.

S. Opal, F. Silverblatt, A. Al-alwan, 2010, Medicine and health, Rhode Island.

The Epithelium as a Target in Sepsis

J. Kellum, S. Goldstein, S. Opal, 2016, Shock.

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic

T. van der Poll, T. File, S. Opal, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-alpha, and epithelial cell-derived neutrophil-activating protein-78 in urine of patients with urosepsis.

T. van der Poll, P. Speelman, S. Opal, 2000, The Journal of infectious diseases.

Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-alpha, and epithelial-derived neutrophil-activating protein-78 in urine of patients with urosepsis Olszyna,

S. Deventer, P. Speelman, S. Opal, 2022 .

What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium.

J. Zabriskie, S. Opal, D. Morrison, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Monitoring of tissue oxygenation

G. Büchele, S. Opal, J. Boldt, 2009 .

Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum.

S. Opal, A. Cross, H. Karreman, 2014, Vaccine.

Characterization of Early Cytokine Responses and an Interleukin (IL)-6–dependent Pathway of Endogenous Glucocorticoid Induction during Murine Cytomegalovirus Infection

S. Opal, Andrew H. Miller, B. Pearce, 1997, The Journal of experimental medicine.

Interleukin-10: potential benefits and possible risks in clinical infectious diseases.

S. Opal, P. Grint, J. Wherry, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prospects for a Vaccine to Prevent Bacterial Sepsis

S. Opal, 2002 .

Immunoprophylaxis Against Bacterial Sepsis

J. Zabriskie, S. Opal, A. Cross, 1999 .

Group B streptococcal sepsis in adults and infants. Contrasts and comparisons.

S. Opal, S. Opal, A. Cross, 1988, Archives of internal medicine.

Aspergillus clavatus endocarditis involving a normal aortic valve following coronary artery surgery.

S. Opal, L. Reller, G. Harrington, 1986, Reviews of infectious diseases.

Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.

S. Opal, A. Cross, J. Drabick, 2004, Vaccine.

Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

S. Opal, A. Cross, H. S. Warren, 2003, Vaccine.

Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat.

S. Opal, A. Cross, K. Kim, 1992, Lymphokine and cytokine research.

Bioterrorism and physicians.

S. Opal, A. Artenstein, M. Neill, 2002, Medicine and health, Rhode Island.

Modification of homogeneous resistance in a methicillin-resistant strain of Staphylococcus aureus by acquisition of a beta-lactamase encoding plasmid.

J. Boyce, A. Medeiros, S. Opal, 1989, The Journal of antimicrobial chemotherapy.

Steroids for sepsis and ARDS: this eternal controversy remains with COVID-19

J. Carlet, S. Opal, D. Payen, 2020, The Lancet.

Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance.

S. Opal, A. Cross, D. Kopecko, 1983, Archives of internal medicine.

A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

R. Wunderink, S. Opal, E. Abraham, 2009, Critical care.

Review: Short-course antibiotics in hospital-acquired pneumonia do not affect mortality

S. Opal, 2012, Annals of Internal Medicine.

The Microbial Aspects of Sepsis: Does the Organism and Its Treatment Affect Outcome?

S. Opal, D. Horn, 1999 .

The clinical relevance of endotoxin in human sepsis: a critical analysis

S. Opal, 2002, Journal of endotoxin research.

Whatever happened to the Shwartzman phenomenon?

J. M. Opal, A. Chahin, S. Opal, 2018, Innate immunity.

Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis.

S. Opal, J. Jhung, J. Palardy, 2003, The Journal of infectious diseases.

Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers.

S. Opal, K. Mayer, M. Neill, 1991, Annals of internal medicine.

Evaluation of Imipenem for Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague

G. Drusano, F. Sörgel, S. Opal, 2014, Antimicrobial Agents and Chemotherapy.

Investigation of a food-borne outbreak of salmonellosis among hospital employees.

S. Opal, K. Mayer, J. Brondum, 1989, American journal of infection control.

Inter-Alpha-Inhibitor Proteins Are Endogenous Furin Inhibitors and Provide Protection against Experimental Anthrax Intoxication

S. Opal, A. Artenstein, Y. Lim, 2005, Infection and Immunity.

Aerobactin and alpha-hemolysin as virulence determinants in Escherichia coli isolated from human blood, urine, and stool.

S. Opal, A. Cross, P. Gemski, 1990, The Journal of infectious diseases.

Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals.

S. Opal, J. Jhung, L. Young, 1998, The Journal of infectious diseases.

Survey of purported virulence factors ofEscherichia coli isolated from blood, urine and stool

S. Opal, A. Cross, P. Gemski, 1988, European Journal of Clinical Microbiology and Infectious Diseases.

The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.

S. Opal, A. Cross, J. Sadoff, 1993, The Journal of infectious diseases.

The Interaction Between the Coagulation System and the Systemic Inflammatory Mediators

S. Opal, 2002 .

Immunopathogenesis of Gram-Negative Shock

S. Opal, C. Hubert, 2002 .

New developments in pathophysiology of endotoxins and opportunities for treatment

S. Opal, M. Luchi, 1999 .

Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study.

M. Malamas, S. Opal, Eirini Christaki, 2010, The Journal of infectious diseases.

Protein C levels in severe sepsis.

S. Opal, 2001, Chest.

Antimicrobial Efficacy of Continuous Low-Irradiance Phototherapy Against Multidrug-Resistant Organisms.

S. Opal, G. Rogers, P. Mcmullan, 2022, Photobiomodulation, photomedicine, and laser surgery.

Reply to “Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?”

S. Opal, D. Fedson, J. Jacobson, 2016, mBio.

Basic Components of Immune System Regulation

S. Opal, 1997 .

Plasmid, serotypic, and enterotoxin analysis of Bacillus cereus in an outbreak setting

R. J. Gilbert, S. Opal, B. Debuono, 1988, Journal of clinical microbiology.

Therapeutic rationale for antithrombin III in sepsis

S. Opal, S. Opal, 2000, Critical care medicine.

Prognostic Value of Endotoxemia in Patients with Gram-Negative Bacteremia Is Bacterial Species Dependent

S. Opal, J. Hurley, 2013, Journal of Innate Immunity.

The impact of converting to a biphasic blood-culture system on the overall cost and the incidence of pseudobacteremia.

S. Opal, J. Heelan, E. Brissette, 1992, Diagnostic microbiology and infectious disease.

Clinical Trials of Novel Therapeutic Agents: Why did they fail?

S. Opal, 1995 .

Vaccines Against Bacterial Endotoxins

S. Opal, A. Cross, A. Bhattacharjee, 2002 .

Antibody Therapy for Sepsis: Some Lessons Learned

S. Opal, 2000 .

Lessons learned from clinical trials of sepsis

S. Opal, S. Opal, 1995 .

Minireview: Therapeutic intervention in sepsis with antibody to endotoxin: is there a future?

S. Opal, A. Cross, S. M. Opal, 1994 .

Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis.

S. Opal, J. Palardy, R. Romulo, 1993, The Journal of infectious diseases.

NK and NKT Cell Depletion Alters the Outcome of Experimental Pneumococcal Pneumonia: Relationship with Regulation of Interferon-γ Production

S. Opal, Eirini Christaki, E. Giamarellos‐Bourboulis, 2015, Journal of immunology research.

Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis

S. Opal, J. Jhung, J. Palardy, 1995, Antimicrobial agents and chemotherapy.

Relative concentrations of endotoxin-binding proteins in body fluids during infection

S. Opal, J. Palardy, M. N. Marra, 1994, The Lancet.

Endotoxins and other sepsis triggers.

S. Opal, 2010, Contributions to Nephrology.

Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection

S. Opal, D. Fedson, O. Rørdam, 2020, mBio.

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”

S. Opal, D. Fedson, O. Rørdam, 2020, mBio.

Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis.

S. Opal, J. Jhung, J. Palardy, 1999, Blood.

Group B streptococcal sepsis.

S. Opal, A. Cross, 1992, JAMA.

Potential Role for Human Interleukin-11 in Bacterial Sepsis

S. Opal, J. Keith, 1996 .

The Role of S1PR3 in Protection from Bacterial Sepsis.

S. Opal, B. Shea, 2017, American journal of respiratory and critical care medicine.

Differences Between American and German Medical Students and Physicians in Knowledge of Infectious Diseases

S. Opal, S. Opal, H. Lode, 2000, European Journal of Clinical Microbiology and Infectious Diseases.

The in vivo significance of antibiotic-induced endotoxin release in experimental Gram-negative sepsis

S. Opal, D. Horn, J. Jhung, 1996 .

Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis

V. Bhandari, S. Opal, J. Solomkin, 2019, Scientific Reports.

Streptococcus pyogenes Tuboovarian Abscess: A Potential Sexually Transmitted Disease?

S. Opal, H. Mirza, 2002, Sexually transmitted diseases.

Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis.

S. Lowry, C. Fisher, S. Opal, 1994, Circulatory shock.

History of U.S. military contributions to the study of vaccines against infectious diseases.

J. M. Opal, S. Opal, A. Artenstein, 2005, Military medicine.

Isolating Influenza RNA from Clinical Samples Using Microfluidic Oil-Water Interfaces

S. Opal, A. Tripathi, F. Cui, 2016, PloS one.

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

J. Helterbrand, C. Fisher, A. Simpson, 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance

S. Opal, 2016, Critical Care.

Spontaneous bacterial peritonitis: Analysis of treatment and outcome.

S. Opal, G. Victor, 1991, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

Phagetherapy: Clinical Applications – Critical Appraisal of Randomized Controlled Trials

S. Opal, X. Wittebole, 2020 .

Bioterrorism and physicians.

S. Opal, A. Artenstein, M. Neill, 2002, Annals of internal medicine.

K antigen and serum sensitivity of rough Escherichia coli

S. Opal, A. Cross, P. Gemski, 1982, Infection and immunity.

New Potential Therapeutic Modalities: Antithrombin III

S. Opal, L. Thijs, 1999 .

The Microbial Consequences of Antimediator Therapy for Sepsis

S. Opal, A. Cross, 1997 .

Inter-α-inhibitor Ameliorates Endothelial Inflammation in Sepsis

S. Opal, Y. Lim, S. Garantziotis, 2019, Lung.

Host-pathogen interactions in sepsis.

T. van der Poll, S. Opal, 2008, The Lancet. Infectious diseases.

Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis.

S. Opal, Y. Lim, J. Palardy, 2003, The Journal of infectious diseases.

A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy.

Shunsuke Takenaka, Oreola Donini, B. Finlay, 2016, Journal of biotechnology.

Clinical Trial Design and Outcomes in Patients with Severe Sepsis

S. Opal, 2003, Shock.

Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction.

S. Opal, S M Opal, A A Asp, 1986, The Journal of infectious diseases.

The current understanding of sepsis and research priorities for the future

S. Opal, Steven M Opal, 2013, Virulence.

Severe Sepsis and Septic Shock

S. Opal, 2008, Surgery.

The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.

S. Opal, 2007, International journal of medical microbiology : IJMM.

The immunopathogenesis of sepsis in elderly patients.

E. Ely, S. Opal, T. Girard, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pansinusitis caused by the fungus Drechslera.

S. Opal, W. H. Harpster, C. Gonzalez, 1985, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Sepsis in the Severely Immunocompromised Patient

S. Opal, A. Kalil, 2015, Current Infectious Disease Reports.

Malaria in travelers in Rhode Island: a review of 26 cases.

S. Opal, G. Olds, R. Romulo, 1991, The American journal of medicine.

Mycobacterium avium complex empyema in a patient with interferon gamma autoantibodies.

S. Opal, T. Deleon, J. Dworkin, 2014, Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health.

Immunotherapy for sepsis--a new approach against an ancient foe.

R. Hotchkiss, S. Opal, 2010, The New England journal of medicine.

Intracranial infection by Vibrio alginolyticus following injury in salt water

S. Opal, J. Saxon, 1986, Journal of clinical microbiology.

Differential antibiotic-induced endotoxin release in severe melioidosis.

A. Simpson, S. Opal, N. White, 2000, The Journal of infectious diseases.

Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection

J. Orange, S. Opal, C. Biron, 1997, Journal of virology.

Molecular Mechanisms of Antibiotic Resistance in Bacteria

S. Opal, A. Pop-Vicas, 2010 .

Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa.

J. McClain, S. Opal, A. Cross, 1989, The Journal of infectious diseases.

Ligation with nucleic acid sequence-based amplification.

S. Opal, A. Artenstein, A. Tripathi, 2012, The Journal of molecular diagnostics : JMD.

69 – The Potential Role of Infectious Agents in Diseases of Unknown Etiology

S. Opal, 2017 .

Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy

S. Opal, D. Horn, M. F. Coronel, 2017, World journal of stem cells.

Future perspectives on regulating pro-and anti-inflammatory responses in sepsis.

S. Opal, D. Delsesto, 2011, Contributions to microbiology.

A Monoclonal Antibody Against RAGE Alters Gene Expression and is Protective in Experimental Models of Sepsis and Pneumococcal Pneumonia

S. Opal, Eirini Christaki, J. Palardy, 2011, Shock.

Novel approaches to the treatment of systemic anthrax.

S. Opal, A. Artenstein, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The evolution of the understanding of sepsis, infection, and the host response: a brief history.

S. Opal, 2011, Critical care nursing clinics of North America.

The evolution of the understanding of sepsis, infection, and the host response: a brief history.

S. Opal, 2009, Critical care clinics.

Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis.

S. Opal, A. Cross, H. S. Warren, 2001, The Journal of infectious diseases.

Immunotherapy of sepsis: flawed concept or faulty implementation?

P. Peduzzi, S. Opal, A. Cross, 1999, Vaccine.

K Antigen andSerumSensitivity ofRoughEscherichia coli

S. Opal, A. Cross, 1982 .

Choice of bacteria in animal models of sepsis

S. Opal, A. Cross, J. Sadoff, 1993, Infection and immunity.

Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.

J. Vincent, D. Angus, R. Schein, 2013, JAMA.

Bactericidal Permeability Increasing Protein: A Potent Naturally Occurring Anti-Endotoxin Protein

S. Opal, M. N. Marra, C. Fisher, 1992 .

Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study.

S. Opal, T. Welte, R. Dellinger, 2015, Respiratory medicine.

Endotoxin's role in Gram-negative bacterial infection

S. Opal, A. Cross, 1995 .

Age, exercise, and the outcome of sepsis

S. Opal, D. Banerjee, 2017, Critical Care.

Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.

S. Opal, A. Cross, J. Palardy, 1994, The Journal of infectious diseases.

Severe Sepsis and Septic Shock: Defining the Clinical Problem

S. Opal, 2003, Scandinavian journal of infectious diseases.

Insights into severe sepsis in older patients: from epidemiology to evidence-based management.

E. Ely, S. Opal, T. Girard, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bench-to-bedside review: Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis

C. Esmon, S. Opal, Charles T Esmon, 2002, Critical care.

Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis?

S. Opal, S. Opal, Jonathan Cohen, 1999, Critical care medicine.

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

S. Opal, A. Cross, J. Sadoff, 1996, The Journal of infectious diseases.

Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers

Steven M. Opal, S. Opal, D. Fedson, 2015, mBio.

Pyomyositis in a patient with the acquired immunodeficiency syndrome.

S. Opal, K. Mayer, G. Victor, 1989, Archives of internal medicine.

Emergence and nosocomial transmission of ampicillin-resistant enterococci

J. Boyce, A. Medeiros, S. Opal, 1992, Antimicrobial Agents and Chemotherapy.

Antibiotic Stewardship: Strategies to Minimize Antibiotic Resistance While Maximizing Antibiotic Effectiveness.

S. Opal, C. Cunha, 2018, The Medical clinics of North America.

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

C. Sprung, R. Postier, C. Doig, 2003, JAMA.

The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.

G. Francis, S. Opal, E. Stein, 2015, American journal of respiratory and critical care medicine.

Bench-to-bedside review: Quorum sensing and the role of cell-to-cell communication during invasive bacterial infection

S. Opal, Steven M Opal, Shadaba Asad, 2008, Critical care.

A simple method for amplifying RNA targets (SMART).

S. Opal, A. Artenstein, A. Tripathi, 2012, The Journal of molecular diagnostics : JMD.

A Brief History of Microbiology and Immunology

S. Opal, 2009, Vaccines: A Biography.

Clinical characteristics, management strategies, and cost implications of a statewide outbreak of enterovirus meningitis.

S. Opal, S. Opal, S. Rice, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia.

T. van der Poll, J. G. van den Berg, S. Opal, 2001, Kidney international.

Detection of alignment changes at the open surface of a confined nematic liquid crystal sensor

Maureen K. McCamley, G. Crawford, S. Opal, 2009 .

The controversy over H5N1 transmissibility research

S. Opal, D. Fedson, 2013, Human vaccines & immunotherapeutics.

Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids

J. Orange, B. McEwen, A. Miller, 1995, The Journal of experimental medicine.

Endothelial barrier dysfunction in septic shock

S. Opal, T. Poll, 2015, Journal of internal medicine.

Clinical trials for severe sepsis. Past failures, and future hopes.

S. Opal, S. Opal, A. Cross, 1999, Infectious disease clinics of North America.

Molecular biology of inflammation and sepsis: A primer*

S. Opal, I. Cinel, 2009, Critical care medicine.

Role of Toll-Like Receptors in Infection and Immunity

Steven M. Opal, S. Opal, Patricia Cristofaro, 2012, Drugs.

The Toll-like receptors and their role in septic shock

S. Opal, P. Cristofaro, 2003, Expert opinion on therapeutic targets.

Sepsis Management: Importance of the Pathogen

S. Opal, R. McCulloh, 2018 .

Cytophagic histiocytic panniculitis. Systemic histiocytosis presenting as chronic, nonhealing, ulcerative skin lesions.

S. Opal, J. Fitzpatrick, J. Fitzpatrick, 1985 .

A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis

S. Opal, N. Kaneider, A. Agarwal, 2011, EMBO molecular medicine.

Bench-to-bedside review: Toll-like receptors and their role in septic shock

S. Opal, Christian E. Huber, 2002, Critical care.

Immunologic alterations and the pathogenesis of organ failure in the ICU.

S. Opal, 2011, Seminars in respiratory and critical care medicine.

Why have group A streptococci remained susceptible to penicillin? Report on a symposium.

E L Kaplan, E. Kaplan, A. Tomasz, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

J. Emtage, S. Opal, S. Stephens, 1994, The Journal of experimental medicine.

Innate Immunity and the Kidney

S. Opal, 2019, Critical Care Nephrology.

Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases.

M. Netea, J. Rello, T. Calandra, 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Is genomic medicine finally coming of age for the diagnosis of pneumonia?

S. Opal, 2015, American journal of respiratory and critical care medicine.

Novel Targets for Drug Development

S. Opal, A. Cross, 2017 .

The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock

S. Opal, A. Pop-Vicas, 2013, Virulence.

Antibodies against RAGE in sepsis and inflammation: implications for therapy

S. Opal, E. Lutterloh, 2007, Expert opinion on pharmacotherapy.

A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis

G. Slotman, S. Opal, D. Morrison, 2000, Journal of endotoxin research.

A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsis

Alison J. Scott, A. Chahin, S. Opal, 2021, Innate immunity.

Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis

J. Vincent, J. Zimmerman, C. Fisher, 1993, Critical care medicine.

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

G. Bernard, J. Dhainaut, S. Opal, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibodies for Sepsis: Some Lessons Learnt

S. Opal, 2001 .

Lipopolyamines as a therapeutic strategy in experimental Gram-negative bacterial sepsis

S. Opal, D. Morrison, J. Palardy, 2001, Journal of endotoxin research.

The Treatment of Sepsis with Interleukin-1 Receptor Antagonist

C. Fisher, S. Opal, J. Pribble, 1994 .

The Challenge of Emerging Infections and Progressive Antibiotic Resistance

S. Opal, S. Opal, 2006, Intensive Care Medicine in 10 Years.

Antiendotoxin Strategies for the Prevention and Treatment of Septic Shock

S. Opal, R. Yu, 1998, Drugs.

Optical detection of sepsis markers using liquid crystal based biosensors

Gregory P. Crawford, Maureen K. McCamley, Andrew W. Artenstein, 2007, SPIE BiOS.

Coinfection With Influenza A Virus and Klebsiella oxytoca: An Underrecognized Impact on Host Resistance and Tolerance to Pulmonary Infections

S. Opal, Peter Belenky, A. Jamieson, 2018, Front. Immunol..

New perspectives on immunomodulatory therapy for bacteraemia and sepsis.

S. Opal, 2010, International journal of antimicrobial agents.

Translational research in the development of novel sepsis therapeutics: Logical deductive reasoning or mission impossible?

S. Opal, E. Patrozou, 2009, Critical care medicine.

Is the mortality rate for septic shock really decreasing?

S. Opal, Eirini Christaki, 2008, Current opinion in critical care.

WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock

S. Opal, J. Jhung, J. Palardy, 2006, Critical care medicine.

THE USE OF IMMUNOCOMPROMISED ANIMALS AS MODELS FOR HUMAN SEPTIC SHOCK

S. Opal, A. Cross, 2005, Shock.

THE ACTIVITY OF PATHWAY-SELECTIVE ESTROGEN RECEPTOR LIGANDS IN EXPERIMENTAL SEPTIC SHOCK

S. Opal, J. Jhung, J. Palardy, 2005, Shock.

Severe Sepsis in the Elderly

E. Ely, S. Opal, T. Girard, 2005, Yearbook of Intensive Care and Emergency Medicine 2005.

ACP Medicine

S. Opal, M. d., Christian E. Huber, 2003 .

Microdroplet Sandwich Real-Time RT-PCR for Detection of Pandemic and Seasonal Influenza Subtypes

S. Opal, A. Artenstein, A. Tripathi, 2013, PloS one.

PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS

S. Opal, J. Freudenberg, J. Palardy, 2015, Shock.

Coming soon to an ICU near you: severe pandemic influenza in ICU patients in Spain

S. Opal, 2009, Critical care.

Analysis of an outbreak of penicillinase-producing Neisseria gonorrhoeae in Rhode Island, 1987

S. Opal, B. Debuono, L. W. Lyhte, 1989, Journal of clinical microbiology.

Research into transmissibility of influenza A H5N1: a practical response to the controversy.

S. Opal, D. Fedson, 2012, The Lancet. Infectious diseases.

Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection

G. Maislin, S. Opal, A. Cross, 2019, International Journal of Peptide Research and Therapeutics.

Cell Signaling Pathways of the Innate Immune System During Acute Inflammation

S. Opal, P. Cristofaro, 2007 .

Role of Toll-like receptors in infection and immunity: clinical implications.

S. Opal, P. Cristofaro, 2006, Drugs.

The role of interleukin-10 in critical illness.

S. Opal, Christian E. Huber, 2000, Current opinion in infectious diseases.

Recurrent Burkholderia gladioli Suppurative Lymphadenitis associated with Neutralizing Anti-IL-12p70 Autoantibodies

S. Holland, S. Opal, Lindsey B. Rosen, 2013, Journal of Clinical Immunology.

Activating Immunity to Fight a Foe - A New Path.

R. Hotchkiss, S. Opal, 2020, The New England journal of medicine.

Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin in Patients Hospitalized for Nonsevere Community-Acquired Pneumonia

J. Bolognese, S. Opal, Abla Tannous, 2020, Antimicrobial Agents and Chemotherapy.

Proprotein convertases in health and disease.

S. Opal, A. Artenstein, 2011, The New England journal of medicine.

Should all septic patients be given systemic anticoagulation? No

S. Opal, T. Poll, 2017, Intensive Care Medicine.

A New Paradigm for the Treatment of Sepsis: Is It Time To Consider Combination Therapy?

S. Opal, A. Cross, 2003, Annals of Internal Medicine.

Investigation of a staphylococcal food poisoning outbreak in a centralized school lunch program.

M. S. Richards, S. Opal, P. Gemski, 1993, Public health reports.

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis

M. Levy, G. Phillips, S. Opal, 2018, Critical Care.

Endotoxin and cytokine detection systems as biomarkers for sepsis-induced renal injury.

S. Opal, 2007, Contributions to nephrology.

CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis.

W. Blackwelder, A. Chahin, S. Opal, 2015, The Journal of infectious diseases.

Sepsis and Scientific Revolutions

T. Higgins, S. Opal, A. Artenstein, 2013, Critical care medicine.

Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial.

D. Angus, D. Yealy, R. Lewis, 2018, Annals of the American Thoracic Society.

Comprar Infectious Diseases, 3rd Edition Expert Consult Premium Edition: Enhanced Online Features and Print | Jonathan Cohen | 9780723435037 | Mosby

Jonathan D. Cohen, S. Opal, W. Powderly, 2010 .

Inter-&agr; Inhibitor Proteins: A Novel Therapeutic Strategy for Experimental Anthrax Infection

S. Opal, A. Artenstein, Y. Lim, 2011, Shock.

Year in review 2008: Critical Care - sepsis

S. Opal, S. LaRosa, 2009, Critical care.

A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.

L. Moldawer, E. Bulger, G. Maislin, 2014, JAMA surgery.

Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.

S. Opal, A. Cross, J. Palardy, 2005, The Journal of infectious diseases.

Active Immunization with a Detoxiﬁed Endotoxin Vaccine Protects against Lethal Polymicrobial Sepsis: Its Use with CpG Adjuvant and Potential Mechanisms

S. Opal, A. Cross, J. Palardy, 2005 .

The activity of interleukin-11 in the gastrointestinal tract

S. Opal, J. Keith, 2000 .

Swine flu, pandemics, and critical care

S. Opal, 2009, Critical care.

Chloroquine enhances survival in Bacillus anthracis intoxication.

S. Opal, A. Artenstein, J. Jhung, 2004, The Journal of infectious diseases.

The Value of Animal Models in Endotoxin Research

S. Opal, 2020 .

How do I optimize antibiotic use in critical illness?

S. Opal, C. Cunha, 2020 .

Severe Sepsis and Septic Shock

S. Opal, 2008 .

Communal Living by Bacteria and the Pathogenesis of Urinary Tract Infections

S. Opal, 2007, PLoS medicine.

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

J. Helterbrand, S. Opal, W. Chaowagul, 2006 .

Thrombocytopenia in Intensive Care Patients

S. Opal, M. Levi, J. J. Hofstra, 2007 .

Recombinant human interleukin-11 has anti-inflammatory actions yet does not exacerbate systemic Listeria infection.

S. Opal, J. Palardy, N. Parejo, 2000, The Journal of infectious diseases.

The Genomic Era and 21st Century Medicine: Its Potential Impact in Sepsis Research

S. Opal, 2001 .

Interleukin-11: Potential Therapeutic Activity in Systemic Inflammatory States

S. Opal, James C. KeithJr., 2000 .

New Trends in Escherichia coli O111:B4 J5 Mutant (Rc chemotype) Vaccine Development for Use in Gram-Negative Bacillary Sepsis,

S. Opal, A. Cross, J. Sadoff, 1995 .

Antibiotics, cytokines, and endotoxin: a complex and evolving relationship in gram-negative sepsis.

S. Opal, D. Horn, E. Lomastro, 1996, Scandinavian journal of infectious diseases. Supplementum.

Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.

S. Opal, S. Opal, A. Cross, 1990, The Journal of infectious diseases.

The Epithelium as a Target in Sepsis

J. Kellum, S. Goldstein, S. Opal, 2016, Shock.

Middle East respiratory syndrome (MERS)

S. Opal, C. Cunha, 2014, Virulence.

IL-1ra as a Therapeutic Modality in Sepsis

S. Opal, 1993 .

Therapeutic Rationale for Endotoxin Removal with Polymyxin B Immobilized Fiber Column (PMX) for Septic Shock

S. Opal, H. Shoji, 2021, International journal of molecular sciences.